LTGO (Latigo Biotherapeutics) Revenue: $ Mil (TTM As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

LTGO Latigo Biotherapeutics Inc LTGO
8 GF Score
Price $18.05
View Full Analysis

What is Latigo Biotherapeutics Revenue?

Latigo Biotherapeutics LTGO -1.10% 8 Revenue is $ Mil as of Dec. 2025. GuruFocus rates LTGO with a GF Score™ of 8/100.

Latigo Biotherapeutics's revenue for the six months ended in Dec. 2025 was $0.00 Mil. Latigo Biotherapeutics does not have enough years/quarters to calculate its revenue for the trailing twelve months (TTM) ended in Dec. 2025. Latigo Biotherapeutics's Revenue per Share for the six months ended in Dec. 2025 was $0.00. Latigo Biotherapeutics does not have enough years/quarters to calculate its Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2025.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get other companies' revenue growth rate using Revenue per Share data.

Latigo Biotherapeutics  (NAS:LTGO) Revenue Explanation

In ranking the predictability, companies with more consistent revenue and earnings growth are ranked high with predictability.

Peter Lynch categorized companies according to their revenue growth:


Slow Grower: Inflation < 10-Year Revenue Growth Rate < 10%:
Stalwart: 10% < 10-Year Revenue Growth Rate < 20%:
Fast Grower: 10-Year Revenue Growth Rate > 20%:

His favorite companies are stalwart, those growing between 10-20% a year.

Companies in cyclical industries may see their revenue fluctuate wildly in good years and bad years.

Be Aware

Revenue can be manipulated by changing the way how revenue is booked. Companies may book sales before the payment is received, or before the revenue is fully earned. These will be added to balance sheet items such as account payable or account receivables.

Latigo Biotherapeutics Revenue Related Terms

Latigo Biotherapeutics Revenue Historical Data

* Premium members only.

The historical data trend for Latigo Biotherapeutics's Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Latigo Biotherapeutics Revenue Chart

Latigo Biotherapeutics Annual Data
Trend Dec24 Dec25
Revenue
0.00 0.00

Latigo Biotherapeutics Semi-Annual Data
Dec24 Dec25
Revenue 0.00 0.00

LTGO vs : Revenue Comparison

For the Biotechnology subindustry, Latigo Biotherapeutics's Revenue, along with its competitors' market caps and Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Latigo Biotherapeutics Revenue vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Latigo Biotherapeutics's Revenue distribution charts can be found below:

* The bar in red indicates where Latigo Biotherapeutics's Revenue falls into.


LTGO
8GF Score
Latigo Biotherapeutics Inc LTGO
Revenue is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Latigo Biotherapeutics Revenue Calculation

Also referred as sales, revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top.

Frequently Asked Questions Learn more about Revenue →
What does a Revenue of $ Mil mean?
Latigo Biotherapeutics (LTGO) has a Revenue of $ Mil as of Dec. 2025. Revenue is the total amount a company generates as sales through its operations. View historical data on Latigo Biotherapeutics and its competitors.
Is Latigo Biotherapeutics' Revenue too high?
Latigo Biotherapeutics' current Revenue is $ Mil. Overall, Latigo Biotherapeutics has a GF Score™ of 8/100, reflecting its overall financial health beyond just this single metric.
How does Latigo Biotherapeutics' Revenue compare to ?
Latigo Biotherapeutics' Revenue of $ Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Revenue for a Biotechnology company?
A good Revenue depends on the Biotechnology industry context. However, Revenue should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Revenue mean?
A high Revenue can signal that a stock is expensive relative to its fundamentals. Revenue is the total amount a company generates as sales through its operations. View historical data on Latigo Biotherapeutics and its competitors. Latigo Biotherapeutics's current Revenue is $ Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Latigo Biotherapeutics stock overvalued right now?
Latigo Biotherapeutics (LTGO) has a current Revenue of $ Mil. The current Revenue is $ Mil. Latigo Biotherapeutics' overall GF Score™ is 8/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Revenue calculated?
Revenue is calculated from a company's financial statements. For Latigo Biotherapeutics (LTGO), the current Revenue is $ Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Latigo Biotherapeutics Business Description

Comparable Companies
Address 1300 Rancho Conejo Boulevard, Suite 305, Thousand Oaks, CA, USA, 91320
Latigo Biotherapeutics Inc is a clinical-stage biotechnology company focused on developing non-opioid pain medicines designed to rapidly and effectively stop the transmission of pain without the risk of addiction. Its flagship product candidates, LTG-001 and LTG-321, are oral Nav1.8 inhibitors being developed for the treatment of acute pain. The company is also developing additional Nav1.8 inhibitor candidates using alternative formulations and delivery approaches.
8GF Score

Get the complete analysis for LTGO

Revenue is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$18.05
Price